Literature DB >> 1983923

Trends in the content and use of oral contraceptives in the United States, 1964-88.

B B Gerstman1, T P Gross, D L Kennedy, R C Bennett, D K Tomita, B V Stadel.   

Abstract

Drug marketing and physician survey data were used to examine trends in the use and hormonal content of oral contraceptives in the United States between 1964 and 1988. Retail prescriptions for oral contraceptives peaked at approximately 68 million in 1973 and have remained between 50 million and 60 million since 1981. Despite this relative consistency in the number of prescriptions, physician "mentions" of oral contraceptives have increased by approximately 75 percent. This increase may reflect closer monitoring of women on oral contraceptives. Use of multiphasic formulations has steadily risen, accounting for 37 percent of the oral contraceptive prescriptions in 1988. Mean estrogen and progestin doses in all types of formulations have steadily declined. A change in the type of estrogen and progestin used in preparations has coincided with this decline in dose. The association between age and use of high-dose formulations seen in the past was no longer evident in 1988. The data demonstrate that oral contraceptive formulations in wide use today differ in hormone content from those of the past, when most of the major studies addressing the risks associated with oral contraceptive use were completed. There is therefore a need to determine the risks and long-term effects associated with these newer formulations.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1983923      PMCID: PMC1404924          DOI: 10.2105/ajph.81.1.90

Source DB:  PubMed          Journal:  Am J Public Health        ISSN: 0090-0036            Impact factor:   9.308


  25 in total

1.  Thrombosis with low-estrogen oral contraceptives.

Authors:  P D Stolley; J A Tonascia; M S Tockman; P E Sartwell; A H Rutledge; M P Jacobs
Journal:  Am J Epidemiol       Date:  1975-09       Impact factor: 4.897

2.  Oral contraceptive use in older women and fatal myocardial infarction.

Authors:  J I Mann; W H Inman; M Thorogood
Journal:  Br Med J       Date:  1976-08-21

3.  Estrogen potency of oral contraceptive pills.

Authors:  H J Chihal; R D Peppler; R P Dickey
Journal:  Am J Obstet Gynecol       Date:  1975-01-01       Impact factor: 8.661

4.  Oral contraceptives, antithrombin- III activity, and postoperative deep-vein thrombosis.

Authors:  S Sagar; J D Stamatakis; D P Thomas; V V Kakkar
Journal:  Lancet       Date:  1976-03-06       Impact factor: 79.321

5.  Oral contraceptives and blood pressure.

Authors:  I R Fisch; J Frank
Journal:  JAMA       Date:  1977-06-06       Impact factor: 56.272

6.  Progestogens and cardiovascular reactions associated with oral contraceptives and a comparison of the safety of 50- and 30-microgram oestrogen preparations.

Authors:  T W Meade; G Greenberg; S G Thompson
Journal:  Br Med J       Date:  1980-05-10

7.  Risk factors for benign breast disease.

Authors:  L A Brinton; M P Vessey; R Flavel; D Yeates
Journal:  Am J Epidemiol       Date:  1981-03       Impact factor: 4.897

8.  Oral contraceptives and thromboembolic disease: effects of lowering oestrogen content.

Authors:  L E Böttiger; G Boman; G Eklund; B Westerholm
Journal:  Lancet       Date:  1980-05-24       Impact factor: 79.321

9.  Surgery, venous thrombosis and anti-Xa.

Authors:  J D Stamatakis; D Lawrence; V V Kakkar
Journal:  Br J Surg       Date:  1977-10       Impact factor: 6.939

View more
  18 in total

1.  Types of combined oral contraceptives used by US women.

Authors:  Kelli Stidham Hall; James Trussell
Journal:  Contraception       Date:  2012-07-06       Impact factor: 3.375

2.  Oral contraceptive use and estrogen/progesterone receptor-negative breast cancer among African American women.

Authors:  Lynn Rosenberg; Deborah A Boggs; Lauren A Wise; Lucile L Adams-Campbell; Julie R Palmer
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-07-20       Impact factor: 4.254

3.  Oral contraceptives and breast cancer risk overall and by molecular subtype among young women.

Authors:  Elisabeth F Beaber; Kathleen E Malone; Mei-Tzu Chen Tang; William E Barlow; Peggy L Porter; Janet R Daling; Christopher I Li
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-03-14       Impact factor: 4.254

4.  Female reproductive factors, menopausal hormone use, and Parkinson's disease.

Authors:  Rui Liu; Donna Baird; Yikyung Park; Neal D Freedman; Xuemei Huang; Albert Hollenbeck; Aaron Blair; Honglei Chen
Journal:  Mov Disord       Date:  2013-12-18       Impact factor: 10.338

Review 5.  Oral contraception and the risk of thromboembolism: what does it mean to clinicians and their patients?

Authors:  James Drife
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

Review 6.  20 µg versus >20 µg estrogen combined oral contraceptives for contraception.

Authors:  Maria F Gallo; Kavita Nanda; David A Grimes; Laureen M Lopez; Kenneth F Schulz
Journal:  Cochrane Database Syst Rev       Date:  2013-08-01

7.  Hormonal and reproductive factors and risk of postmenopausal thyroid cancer in the NIH-AARP Diet and Health Study.

Authors:  S J Schonfeld; E Ron; C M Kitahara; A Brenner; Y Park; A J Sigurdson; A Schatzkin; A Berrington de González
Journal:  Cancer Epidemiol       Date:  2011-08-17       Impact factor: 2.984

8.  A case-control study of oral contraceptive use and incident breast cancer.

Authors:  Lynn Rosenberg; Yuqing Zhang; Patricia F Coogan; Brian L Strom; Julie R Palmer
Journal:  Am J Epidemiol       Date:  2008-12-13       Impact factor: 4.897

9.  Oral contraceptive use and breast cancer risk among African-American women.

Authors:  J R Palmer; L Rosenberg; R S Rao; B L Strom; M E Warshauer; S Harlap; A Zauber; S Shapiro
Journal:  Cancer Causes Control       Date:  1995-07       Impact factor: 2.506

10.  Recent oral contraceptive use by formulation and breast cancer risk among women 20 to 49 years of age.

Authors:  Elisabeth F Beaber; Diana S M Buist; William E Barlow; Kathleen E Malone; Susan D Reed; Christopher I Li
Journal:  Cancer Res       Date:  2014-08-01       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.